1315 Capital II, L.P. - 20 Jan 2026 Form 4 Insider Report for INTERPACE BIOSCIENCES, INC. (IDXG)

Role: 10%+ Owner
Signature: 1315 Capital II, L.P. By: 1315 Capital GP II, L.P., its general partner; By: 1315 Capital Ultimate Holdings, LLC, its general partner; By: Adele C. Oliva, Sole Member /s/ Adele C. Oliva
Issuer symbol: IDXG
Transactions as of: 20 Jan 2026
Net transactions value: +$19,000,001
Form type: 4
Filing time: 17 Feb 2026, 16:05:12 UTC
Previous filing: 15 Oct 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
1315 Capital II, L.P.	10%+ Owner	C/O INTERPACE BIOSCIENCES, INC., WATERVIEW PLAZA, SUITE 310 2001 ROUTE 46, PARSIPPANY	1315 Capital II, L.P. By: 1315 Capital GP II, L.P., its general partner; By: 1315 Capital Ultimate Holdings, LLC, its general partner; By: Adele C. Oliva, Sole Member /s/ Adele C. Oliva	17 Feb 2026	0001730825

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IDXG	Common Stock	Conversion of derivative security	$19,000,001	+9,405,941		$2.02	9,405,941	20 Jan 2026	Direct	F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDXG	Series C Convertible Preferred Stock	Conversion of derivative security	$0	-19,000	-100%	$0.000000	0	20 Jan 2026	Common Stock	9,405,941	$2.02	Direct	F1, F2, F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 20, 2026, 19,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 9,405,941 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").
F2	The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.
F3	These securities are held of record by 1315 Capital II, L.P. (the "Investor"). 1315 Capital GP II, L.P. ("1315 Capital GP") is the general partner of the Investor and 1315 Capital Ultimate Holdings, LLC ("1315 Capital Ultimate") is the general partner of 1315 Capital GP. By virtue of such relationship, each of 1315 Capital GP and 1315 Capital Ultimate may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.
F4	Each of 1315 Capital GP and 1315 Capital Ultimate disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F5	The Series C Convertible Preferred Stock had no expiration date.